UP!

CBLI $2.23   View long term graphs

Cleveland BioLabs
Type
Public
Traded as NASDAQ: CBLI
Industry Pharmaceuticals
Founded Cleveland, Ohio, 2003
Headquarters Buffalo, New York, USA
Key people

Yakov Kogan, CEO

Andrei Gudkov, Chief Scientific Officer

Neil Lyons, Chief Financial Officer
Products Anti-radiation and oncological products
Subsidiaries Incuron, LLC
Panacela Labs, Inc.
Website www.cbiolabs.com

Yakov Kogan, CEO

Andrei Gudkov, Chief Scientific Officer

Cleveland BioLabs, Inc. (Nasdaq: CBLI) is a clinical-stage biotechnology company with a focus on oncology development. It specializes in research and development of products with the potential to treat cancer and protect against death following acute radiation syndrome. The company was founded in 2003 and is headquartered in Buffalo, New York. It has license agreements and collaborations with the Cleveland Clinic, Roswell Park Cancer Institute, the Children’s Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute.

Cleveland BioLabs was founded in partnership with the Cleveland Clinic in 2003 and moved to the Buffalo Niagara Medical Campus in 2007.

The following table shows key financial figures for the company for 2011, 2012 and 2013 (parenthesis represent negative figures).

Cleveland Biolabs has two majority-owned subsidiaries:

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2018 2018-05-15 0.00 -0.11
Q4 2017 2018-03-06 0.00 -0.10
Q3 2017 2017-11-14 0.00 -0.11
Q2 2017 2017-08-14 0.00 -0.50
Q1 2017 2017-05-15 0.00 -0.15
Q4 2016 2017-02-22 0.00 -0.11
Q3 2016 2016-11-14 0.00 0.10
Q2 2016 2016-08-15 0.00 -0.17
Q1 2016 2016-05-16 0.00 -0.06
Q4 2015 2016-02-22 0.00 -0.13

Ratings

2014-01-24 Downgrade Oppenheimer Outperform to Market Perform $0.75 to $1.13
2014-01-24 Downgrade Cantor Fitzgerald Buy to Hold $4.00 to $2.00
2013-03-21 Initiated Cantor Fitzgerald Buy $4
2012-12-06 Initiated Oppenheimer Outperform $3
2012-12-04 Initiated Burrill Institutional Research Mkt Outperform $4
2011-02-02 Initiated Wedbush Outperform $10
2010-10-13 Downgrade WBB Securities Strong Buy to Hold $6.50 to $6.50
2010-09-17 Reiterated Rodman & Renshaw Mkt Outperform $8 to $11
2010-07-21 Downgrade WBB Securities Strong Buy to Speculative Buy $6.50
2009-09-29 Initiated Rodman & Renshaw Mkt Outperform $8
2014-01-24 Downgrade Oppenheimer Outperform to Market Perform $0.75 to $1.13
2014-01-24 Downgrade Cantor Fitzgerald Buy to Hold $4.00 to $2.00
2013-03-21 Initiated Cantor Fitzgerald Buy $4
2012-12-06 Initiated Oppenheimer Outperform $3
2012-12-04 Initiated Burrill Institutional Research Mkt Outperform $4

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Gudkov Andrei V Chief Scientific Officer 2.66%  (1517370) CBLI /
Fonstein Michael CEO, President 2.06%  (1176465) CBLI /
BROWN JULIA R 0.20%  (116482) BIOD / CBLI / TRGT /
Principi Anthony 0.09%  (52419) CBLI / EGL / IMMY /
Hohn David C 0.08%  (43049) CBLI /
DiCorleto Paul E 0.07%  (41968) CBLI /
KASTEN BERNARD L 0.05%  (26998) CBLI / ENZ /
Lyons C Neil Chief Financial Officer 0.04%  (20273) CBLI /
Kogan Yakov COO, Secretary 0.03%  (17377) CBLI /
Perez Hector Daniel 0.02%  (12749) CBLI /
Antal James 0.01%  (8000) CBLI / SIGA /
SALUCK RANDY S. 0.01%  (6116) CBLI /

Comments